Redhill Biopharma (RDHL) Projected to Post Quarterly Earnings on Monday

Redhill Biopharma (NASDAQ:RDHL) is anticipated to post its H2 24/25 resultson Monday, March 30th. Analysts expect Redhill Biopharma to post earnings of ($352.8571) per share and revenue of $24.2860 million for the quarter. Interested persons can find conference call details on the company’s upcoming H2 24/25 earning report page for the latest details on the call scheduled for Wednesday, April 8, 2026 at 6:00 PM ET.

Redhill Biopharma Trading Down 4.0%

Shares of Redhill Biopharma stock opened at $0.75 on Friday. The firm has a market capitalization of $3.83 million, a PE ratio of 0.00 and a beta of 4.91. Redhill Biopharma has a 12 month low of $0.75 and a 12 month high of $3.31. The business’s 50-day moving average price is $1.02 and its 200-day moving average price is $1.26.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Redhill Biopharma in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.